|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan
| Title: | Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan |
| Authors: | Atsumi, Tatsuya Browse this author →KAKEN DB | | Asakura, Eri Browse this author | | Doi, Michio Browse this author | | Sawant, Ruta Browse this author | | Kawaguchi, Isao Browse this author | | Sasaki, Nobuhito Browse this author | | Liew, Danny Browse this author |
| Keywords: | Cost per responder | | Janus kinase inhibitor | | Japan | | number needed to treat | | rheumatoid arthritis |
| Issue Date: | Jan-2023 |
| Publisher: | Oxford University Press |
| Journal Title: | Modern rheumatology |
| Volume: | 33 |
| Issue: | 1 |
| Start Page: | 54 |
| End Page: | 63 |
| Publisher DOI: | 10.1093/mr/roac015 |
| Abstract: | Objective This study evaluated the effectiveness and cost-effectiveness of baricitinib, tofacitinib, and upadacitinib regimens, compared to conventional synthetic disease-modifying antirheumatic drug (csDMARD) alone, among Japanese patients with moderate-to-severe rheumatoid arthritis (RA) inadequately responsive to csDMARD, measured in terms of number needed to treat (NNT) and cost per responder (CPR). Methods Efficacy data were derived from two recent network meta-analyses among global and Japanese population. The cost perspective was that of the Japanese Health Service. Both NNT and CPR were based on disease activity score for 28 joints with C-reactive protein (DAS28-CRP) remission and American College of Rheumatology (ACR) 20/50/70 at 12 and 24 weeks. Results Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 [USD 16,361], respectively, for upadacitinib 15 mg + csDMARD. The equivalent results were 6.0 and JPY 2,691,684 [USD 24,470] for baricitinib 4 mg + csDMARD and 5.6 and JPY 2,507,152 [USD 22,792] for tofacitinib 5 mg + csDMARD. Similar rankings were observed at 24 weeks and for other outcomes. Conclusions Upadacitinib 15 mg was associated with the lowest NNT and CPR among the three Janus kinase inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/87939 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
